Elevar Therapeutics

Elevar Therapeutics is a fully integrated, oncology-focused biopharmaceutical company dedicated to developing and commercializing innovative therapies for patients with limited or inadequate treatment options. The company leverages rigorous scientific expertise to advance a pipeline of promising medicines for complex, under-treated conditions. As a majority-owned subsidiary of the HLB Group, Elevar operates with a global perspective, actively pursuing strategic partnerships to expand the reach of its therapeutic assets. The company is currently focused on the regulatory advancement and potential commercialization of key oncology candidates, including lirafugratinib and the combination of rivoceranib and camrelizumab.